View Post

Pfizer Gains Priority Review For Breast Cancer Drug, Can It Succeed?

In In The News by Barbara Jacoby

By: Terry Chrisomalis From: Summary Pfizer obtains priority review for talazoparib in treating patients with germline BRCA-mutated breast cancer, with FDA decision date by December 2018. Treatment with talazoparib in BRCA-mutated breast cancer reduced the risk of disease progression by 46%. If talazoparib is approved by the FDA it will have to go up against other competing drugs for the same …